After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion. This is the first new class of treatment for the psychiatric disorder since ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.
The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...
The target of the strike in Lebanon was the group’s leader, Hassan Nasrallah, according to Israeli and American officials. The attack came shortly after the Israeli prime minister gave a defiant ...
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
Eric Adams Awaits Arraignment in Court on Bribery and Fraud Charges The New York mayor was scheduled to be arraigned today. He has insisted he will stay in office and asked New Yorkers to give him ...
Get the latest Australian and world news covering breaking news and trending topics that educate, engage and entertain. Learn more about where you live, the language you speak, and how the country ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback